A newborn baby develops cyanosis on day three of life. On auscultation, there is a systolic murmur. Echocardiography reveals a cyanotic heart disease in the baby. Which one of the following drugs can be intervention -administered to prolong the life of the baby pending intervention –
First, I need to recall the common cyanotic heart diseases in newborns. Tetralogy of Fallot (TOF) is a classic one, but there's also Transposition of the Great Arteries (TGA), Tricuspid Atresia, and others. The timing here is day three, which might be relevant. For example, TGA typically presents with cyanosis at birth, but symptoms may worsen around day 3-5 because of the closure of the ductus arteriosus. So if the ductus is closed, the mixing of blood stops, leading to severe cyanosis.
In TGA, the main treatment before surgery is to keep the ductus arteriosus open. Prostaglandin E1 (PGE1) is used for this. It's a drug that prevents the ductus from closing. So if the baby has TGA, giving PGE1 would maintain the ductus open, allowing mixing of oxygenated and deoxygenated blood, thereby improving oxygenation until surgery can be done.
Other options might include drugs like indomethacin, which is used to close the ductus in preterm infants with PDA, but that's the opposite here. If the question is about keeping the ductus open, then PGE1 is correct.
So the core concept here is that in cyanotic heart disease where ductal patency is crucial, like TGA, PGE1 is administered to keep the ductus open. The correct answer should be PGE1. The incorrect options would be drugs that either close the ductus or don't affect it. Let me make sure there aren't other drugs used in similar situations. For example, in TOF, the management might involve morphine or beta-blockers, but those don't keep the ductus open. So the key here is TGA and PGE1.
**Core Concept** The question tests knowledge of pharmacologic management in cyanotic congenital heart disease, specifically the use of ductus arteriosus maintenance in transposition of the great arteries (TGA). Prostaglandin E1 (PGE1) is critical to delay ductal closure until surgical intervention.
**Why the Correct Answer is Right** In TGA, the aorta arises from the right ventricle and the pulmonary artery from the left ventricle, causing parallel circulations. A patent ductus arteriosus (PDA) allows mixing of oxygenated and deoxygenated blood, improving systemic oxygenation. PGE1 inhibits ductus constriction by reducing prostaglandin synthase activity, maintaining PDA patency. This is life-saving until an arterial switch operation can be performed.
**Why Each Wrong Option is Incorrect**
**Option A:** Indomethacin/ibuprofen closes the ductus and worsens cyanosis in TGA.
**Option B:** Beta-blockers reduce systemic vascular resistance but are not used to maintain ductal patency.
**Option C:** Diuretics are ineffective in this context and may exacerbate hypovolemia.
**Clinical Pearl** Remember the "3 Ds" for